ABOUT ANTICANCER, INC.

History:

Founded in 1984.
Oldest free-standing Biotechnology Company in the San Diego cluster.

Employees:

35 including 20 PhDs and MDs. [CLICK HERE FOR THE PHOTO OF COMPANY EMPLOYEES]

Products:

TOOLS

Oncobrite^â

The leading small-animal imaging Technology
OncoBrite^â Imaging Technology is based on green fluorescent protein (GFP) and related fluorescent proteins.
OncoBrite^â can image tumor growth, metastasis, angiogenesis, tumor cell trafficking, gene expression and other in vivo processes in real time.
The leading technology for real-time drug discovery.
More than one hundred cancer cell lines engineered with fluorescent proteins.
The Olympus OV100 Whole Mouse Imaging system is designed for OncoBrite^â Technology.
See Publications list (PDF Library)
Contact Li Tang, Business Development Manager, for licensing, contract research and equipment: all@anticancer.com
OncoBrite^â patents:

US: 6,232,523; 6,235,967; 6,759,038; 6,235,968; 6,251,384; 6,649,159; 6,905,831

Europe: 0979298; 1156833; 1294906

Japan: 3,709,343; 4,021,197

China: 03823937X

Germany: 60137501708

Korea: 10-868200

Australia: 749,338; 2003272221; 2001249297

Canada: 2,289,283; 2,358,439

Numerous worldwide patents pending

MetaMouse^â- ANGIOMOUSE^â

The leading mouse models of human cancer.
Patient-like mouse models of human metastatic cancer and angiogenesis.
Models of all cancer types.
The only patient-like models for metastasis and angiogenesis drug discovery.
Technology uses surgical orthotopic implantation (SOI) of human cancer cell lines and patient tumors.
Tumor growth and metastasis in MetaMouse^â - AngioMouse^â mimics clinical cancer.
More than one hundred MetaMouse^â- AngioMouse^â- OncoBrite^â imageable mouse models are available.
See Publication list (PDF Library)
Contact Li Tang, Business Development Manager, for licensing and contract research.
MetaMouse^â patents:

US: 5,491,284; 5,569,812 Reissue RE:39,337

Japan: 2,664,261

Europe: 0437488

HDRA^â

· Histoculture Drug Response Assay

· Individualized Cancer Therapy

· In vitro drug sensitivity and resistance for solid tumors specimens from all patients for optimal drug treatment

· HDRA results correlate with patient survival

· See publication list (PDF Library)

· Contact Li Tang, Business Development Manager, for cancer patient testing and drug discovery screening: all@anticancer.com

· HDRA^â Patents:

US: 5,424,909; 5,474,909; 5,726,009; 7,252,941

Europe: 714,448; 1,567,672

Japan: 4,336,654

China: ZL200380108676.2

THERAPEUTICS

Oncase-PEG^â

PEGylated recombinant methioninase (PEG-rMETase)
Recombinant protein depletes methionine in tumors
Tumor growth arrested and drug sensitivity induced
Active against all cancer types
IND filing in preparation
See publication list (PDF Library)
Contact Li Tang, Business Development Manager, for ONCase-PEG^â licensing opportunities: all@anticancer.com
ONCase-PEG^â Patents:

US: 5,690,929; 5,715,835; 5;861,154; 5,863,788; 5,888,506; 5,891,704; 6,231,854; 6,461,851; 6,524,571; 6,632,430; 7,264,819; 7,329,516; 7,799,549

Japan: 2,930,723

Europe: 668,933; 839,055; 1,005,557; 1,287,830; 1,183,034

Australia: 687,768; 708,361; 752,107

China: ZL96190574.3; ZL200480017595.6

Canada: 2,375,383; 2,149,776

STEM CELLS

Pluripotent hair follicle stem cells for general regenerative medicine
Hair follicle stem cells for nerve regeneration
See Publication list (PDF Library)
Hair follicle stem cell therapeutic patents:

US and worldwide patents pending

Contact Li Tang, Business Development Manager, for hair follicle stem cells therapeutic licensing: all@anticancer.com

Stem cells Patents:

Europe 1677606

China ZL200480039243.0

TUMOR-TARGETING BACTERIA

Salmonella typhimurium A1 auxotroph targets prostate and breast cancer
Additional Salmonella typhimurium auxotrophs are being developed to target other tumor types
See publication list (PDF Library)
Contact Li Tang, Business Development Manager, for licensing: all@anticancer.com
Tumor-targeting bacteria patents:

Patents: Japan 4350519

US and worldwide patents pending

DRUG DELIVERY

DERMATEK^â

· Liposome-based hair-follicle targeting Technology

· Small and large molecules can be targeted to the hair follicle

· Hair follicle gene therapy

· 3-D culture of full thickness skin for hair growth stimulator and pigment modifier discovery

· See publication list (PDF Library)

· Contact Li Tang, Business Development Manager, for DermaTek^â licensing and contract research: all@anticancer.com

· DermaTek^âPatents:

US: 5,641,508; 5,646,508; 5,753,263; 5,830,177; 5,849,579; 5,914,126; 5,965,157; 6,080,127; 6,224,901; 6,261,596; 6,399,380; 6,733,776; 6,844,326; 7,556,825; 7,666,675

Japan: 2,950,519; 2,950,520; 3,978,179

China: ZL02823052.3

Europe: 573,606; 692,972

South Korea: 10-973424

Canada: 2,159,626

Australia: 2002336742, 731,559

DIAGNOSTICS

A/C Diagnostics, LLC

AntiCancer Subsidiary

· Enzymatic Homocysteine Assay

· The simplest, least expensive homocysteine assay

· 510 (k) cleared

· Automated on Hitachi 912 and related instruments

· Portable assay with 2 kg portable fluorescence reader

· Enzymatic Homocysteine Assay Patents:

US: 5,985,540; 5,998,191; 6,066,467; 6,140,102; 6,448,446; 6,468,762; 6,713,273

Japan: 3,337,693

Europe: 1,000,170, 1,265,846; 1,250,448

Australia: 758729; 2001229460

South Korea: 10-0682292

China: ZL98807531.8

· Enzymatic B₆ assay

· Only non-radioactive enzymatic assay for B6

· Microtiter plate format

· Automated with TECAN FREEDOM EVO

· Enzymatic B₆ Assay Patents:

US: 6,426,194

Australia: 765,931

Japan: 4,098,475

China: ZL 00803327.7

Worldwide patents pending

· Enzymatic cysteine assay

· Simple enzymatic assay for cysteine

· Suitable for automation on numerous platforms

· See publication list (PDF Library) for all A/C Diagnostics Publications

· Contact Li Tang, Business Development Manager, for all A/C Diagnostics products: all@anticancer.com

· Enzymatic Cysteine Assay Patents:

US: 6,927,038;

Europe: 1,456,399

China: ZL02823051.5

Australia: 2002346474

Japan: 4319545

Canada: 2,466,503

South Korea: 10-976967